Tianjin Ringpu Bio-Technology Co.,Ltd.

SZSE:300119 Stock Report

Market Cap: CN¥8.5b

Tianjin Ringpu Bio-TechnologyLtd Valuation

Is 300119 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300119 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300119 (CN¥18.4) is trading below our estimate of fair value (CN¥31.46)

Significantly Below Fair Value: 300119 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300119?

Key metric: As 300119 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 300119. This is calculated by dividing 300119's market cap by their current earnings.
What is 300119's PE Ratio?
PE Ratio20x
EarningsCN¥423.98m
Market CapCN¥8.48b

Price to Earnings Ratio vs Peers

How does 300119's PE Ratio compare to its peers?

The above table shows the PE ratio for 300119 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average17.5x
002275 Guilin Sanjin Pharmaceutical
21x13.7%CN¥8.6b
600557 Jiangsu Kanion PharmaceuticalLtd
14.9x19.0%CN¥8.1b
600789 Shandong Lukang PharmaceuticalLtd
19xn/aCN¥7.6b
600664 Harbin Pharmaceutical Group
15.1xn/aCN¥9.3b
300119 Tianjin Ringpu Bio-TechnologyLtd
20x18.3%CN¥8.5b

Price-To-Earnings vs Peers: 300119 is expensive based on its Price-To-Earnings Ratio (20x) compared to the peer average (17.5x).

Price to Earnings Ratio vs Industry

How does 300119's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
300119 20.0xIndustry Avg. 31.1xNo. of Companies31PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 300119 is good value based on its Price-To-Earnings Ratio (20x) compared to the CN Pharmaceuticals industry average (31.1x).

Price to Earnings Ratio vs Fair Ratio

What is 300119's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300119 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio20x
Fair PE Ratio25x

Price-To-Earnings vs Fair Ratio: 300119 is good value based on its Price-To-Earnings Ratio (20x) compared to the estimated Fair Price-To-Earnings Ratio (25x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 300119 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥18.40
CN¥20.60
+12.0%
10.6%CN¥24.00CN¥18.00n/a5
Nov ’25CN¥18.37
CN¥19.90
+8.3%
8.1%CN¥21.56CN¥17.50n/a5
Oct ’25CN¥15.08
CN¥17.97
+19.2%
9.4%CN¥21.00CN¥16.39n/a5
Sep ’25CN¥12.09
CN¥17.97
+48.6%
9.4%CN¥21.00CN¥16.39n/a5
Aug ’25CN¥13.43
CN¥19.56
+45.7%
5.0%CN¥21.00CN¥18.45n/a5
Jul ’25CN¥14.00
CN¥20.39
+45.6%
10.0%CN¥24.50CN¥18.45n/a6
Jun ’25CN¥15.28
CN¥21.14
+38.3%
9.4%CN¥24.50CN¥18.50n/a5
May ’25CN¥16.39
CN¥21.14
+29.0%
9.4%CN¥24.50CN¥18.50n/a5
Apr ’25CN¥15.99
CN¥20.97
+31.2%
9.9%CN¥24.50CN¥18.50n/a5
Mar ’25CN¥14.59
CN¥21.74
+49.0%
12.1%CN¥24.50CN¥17.70n/a5
Feb ’25CN¥13.43
CN¥21.74
+61.8%
12.1%CN¥24.50CN¥17.70n/a5
Jan ’25CN¥16.39
CN¥23.04
+40.5%
13.1%CN¥26.50CN¥17.70n/a5
Dec ’24CN¥17.29
CN¥23.04
+33.2%
13.1%CN¥26.50CN¥17.70n/a5
Nov ’24CN¥17.22
CN¥23.04
+33.8%
13.1%CN¥26.50CN¥17.70CN¥18.375
Oct ’24CN¥18.28
CN¥23.59
+29.0%
14.3%CN¥26.50CN¥17.70CN¥15.085
Sep ’24CN¥19.02
CN¥23.21
+22.0%
17.5%CN¥26.50CN¥15.80CN¥12.095
Aug ’24CN¥18.77
CN¥25.50
+35.8%
19.3%CN¥28.90CN¥15.80CN¥13.435
Jul ’24CN¥17.80
CN¥25.50
+43.2%
19.3%CN¥28.90CN¥15.80CN¥14.005
Jun ’24CN¥18.92
CN¥25.50
+34.8%
19.3%CN¥28.90CN¥15.80CN¥15.285
May ’24CN¥21.50
CN¥26.34
+22.5%
12.4%CN¥28.90CN¥20.00CN¥16.395
Apr ’24CN¥21.64
CN¥24.70
+14.1%
14.1%CN¥28.28CN¥19.00CN¥15.994
Mar ’24CN¥22.42
CN¥23.43
+4.5%
12.7%CN¥26.50CN¥19.00CN¥14.594
Feb ’24CN¥20.12
CN¥23.43
+16.5%
12.7%CN¥26.50CN¥19.00CN¥13.434
Jan ’24CN¥18.61
CN¥22.41
+20.4%
12.3%CN¥25.73CN¥19.00CN¥16.393
Dec ’23CN¥19.77
CN¥22.41
+13.4%
12.3%CN¥25.73CN¥19.00CN¥17.293
Nov ’23CN¥20.11
CN¥22.41
+11.4%
12.3%CN¥25.73CN¥19.00CN¥17.223

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥50.2b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥30.49

7D

-2.1%

1Y

7.6%

China Resources Double-Crane PharmaceuticalLtd

CN¥22.7b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

7D

-3.9%

1Y

12.1%

Dong-E-E-JiaoLtd

CN¥37.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥58.25

7D

-1.7%

1Y

16.8%